PVLA Latest Headlines

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

at www.tipranks.com (Wed, 22-Jul 11:00 AM)

Oppenheimer Sticks to Their Buy Rating for Palvella Therapeutics (PVLA)

at www.tipranks.com (Tue, 21-Jul 4:29 PM)

Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price Target

at www.tipranks.com (Tue, 21-Jul 4:19 PM)

Palvella Pharmaceuticals: Buy Rating Reiterated as QTORIN Regulatory Path Stays Intact; Price Target Unchanged at $225

at www.tipranks.com (Tue, 21-Jul 3:18 PM)

Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst

at www.tipranks.com (Tue, 21-Jul 12:26 PM)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD)

at www.tipranks.com (Tue, 21-Jul 12:21 PM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD)

at www.tipranks.com (Tue, 21-Jul 12:11 PM)

Analysts Conflicted on These Healthcare Names: Alcon (ALC), Palvella Therapeutics (PVLA) and Cardinal Health (CAH)

at www.tipranks.com (Tue, 21-Jul 12:02 PM)

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP)

at www.tipranks.com (Mon, 20-Jul 8:50 AM)

PVLA’s QTORIN Rapamycin Shows Statistically Significant Bleeding Reduction in Phase 2 TOIVA Study – 100% Patient Satisfaction Highlighted

Market Chameleon (Fri, 15-May 11:25 AM)